High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors
-
Published:2023-11-20
Issue:3
Volume:18
Page:
-
ISSN:1920-1214
-
Container-title:Canadian Urological Association Journal
-
language:
-
Short-container-title:CUAJ
Author:
Zhang Hanbo,Alimohamed Nimira S.,Basappa Naveen S.,Cheng Tina,Chu Michael,Cox-Kennett Nanette,Ernst D. Scott,Fontaine Amelie,Ghosh Sunita,Heng Daniel Y.C.,Littleton Richard,North Scott,Railton Cindy,Sandhu Irwindeep,Stenson Trevor H.,Stewart Douglas A.,Venner Christopher,Venner Peter C.,Kolinsky Michael P.
Abstract
Introduction: High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is standard therapy for metastatic germ cell tumors (mGCTs) in patients whose disease progresses during or after conventional chemotherapy. We conducted a retrospective review of HDC-ASCT in relapsed mGCT patients in the province of Alberta, Canada over the past two decades.
Methods: Patients with mGCTs who received HDC-ASCT at two provincial cancer referral centers from 2000–2018 were identified from institutional databases. Baseline clinical and treatment characteristics were collected, as well as overall survival (OS) and disease-free survival (DFS). Relevant prognostic variables were analyzed.
Results: Forty-three patients were identified. The median age was 28 years (range 19–56). A majority (95%) had non-seminoma histology and testis/retroperitoneal primary (84%). Twenty patients (47%) had poor-risk disease, as per The International Germ Cell Consensus Classification (IGCCC), at start of first-line chemotherapy. HDC-ASCT was used as second-line therapy in 65% of patients, and 58% of ASCT patients received tandem transplants. Median followup after ASCT was 22 months (range 2–181). At last followup, 42% of patients were alive without disease, including 3/7 (43%) of patients with primary mediastinal disease. Two-year and five-year DFS/OS ratios were 44%/65% and 38%/45%, respectively. Median OS and DFS for all patients were 30.0 months (13.3–46.6) and 8.0 months (0.9–15.1), respectively.
Conclusions: We found that HDC-ASCT is an effective salvage therapy in mGCT, consistent with existing literature. Patients appeared to benefit regardless of primary site. Though limited by small sample size, we found a numerical difference in DFS and OS between second- and third-line HDC-ASCT and single vs. tandem ASCT.
Publisher
Canadian Urological Association Journal